Richard Marsden

CEO of @SynairgenPLC. Finds complete relaxation when sailing. All views on here are my own. #SNG

[Richard Marsden @RichardMSNG]

Entering into 2023, I want to thank the team at Synairgen and our partners and investors for their dedication during 2022. I look forward to continuing making further progress towards our goals this year.

https://t.co/HstqYjqnAH

#SNG

[Richard Marsden @RichardMSNG]

Looking forward to attending and participating in the Disease Prevention and Control Summit. Such a critical conversation to be a part of.

[Synairgen @Synairgenplc]

For #attendees, #media and #investors

Attending the @DPC_Summit 2022 themed “No More Pandemics" at the National Harbor, Washington DC next week?
Our CEO @RichardMSNG will be presenting onsite  Sep 7, at 3:10pm ET.

https://t.co/heV0UvAcq6

#SNG #DPCSummit #NoMorePandemics

[Richard Marsden @RichardMSNG]

Proud of what we’ve accomplished and looking forward to the continued work that lies ahead

[Synairgen @Synairgenplc]

2021 was truly an epic year for Synairgen as we hit important milestones, grew the team and made preparations for the future.

Thank you to our partners for your continued support. Together we are ready to hit the ground running in 2022.

#2021review #2022ready #SNG

[Synairgen @Synairgenplc]

Synairgen is wishing you health and happiness this holiday season and throughout the New Year.
Happy Holidays!

[Richard Marsden @RichardMSNG]

I’d like to add my personal thanks to everyone involved in helping us reach this important milestone

[Synairgen @Synairgenplc]

A huge thank you to the nurses, doctors, and especially the patients hospitalised with COVID-19, part of our SPRINTER trial investigating #SNG001. Thanks to you, we are one step closer to evaluating the potential of an important new therapy.

https://t.co/snfaicYhQB

[Richard Marsden @RichardMSNG]

Great work from Jody Brookes, the whole Synairgen clinical team and our partners in hitting our target! #SNG #SNG001 #Synairgen
https://t.co/tBfc78CGWc

[Richard Marsden @RichardMSNG]

A massive milestone, and during a pandemic, no less! Congratulations to the entire #SNG clinical trials team.

#SNG001 #Synairgen

[Synairgen @Synairgenplc]

We are pleased to announce completion of patient recruitment in our global Phase 3 SPRINTER trial for #SNG001. With the randomisation of our 610th patient, we are one step closer to understanding the potential of SNG001 in the global #COVID battle.

https://t.co/15wrSFipLb

[Richard Marsden @RichardMSNG]

Thank you @proactive_UK . It’s important that we continue to consider not just COVID-19 today, but also the potential needs as the disease evolves

[Synairgen @Synairgenplc]

Following last week’s announcement that #SNG001 is advancing to Phase 3 of the @NIH-sponsored #ACTIV2 trials, CEO Richard Marsden spoke with @Proactive_UK about the future of SNG001 as a potential treatment for #COVID19. Watch: https://t.co/cohIfxliBz #SNG

[Richard Marsden @RichardMSNG]

Thank you to the @ACTGNetwork team. We’re delighted that #SNG001 is progressing to Phase 3 of #ACTIV-2 trialling therapeutics for #COVID19. Tremendous effort.

[Synairgen @Synairgenplc]

ACTG announces graduation of investigational inhaled COVID-19 treatment to phase 3 study in activ-2 https://t.co/b2Yuh5TZud

[Richard Marsden @RichardMSNG]

This is excellent news and reinforces our conviction that #SNG001 has the potential to be an important treatment for #COVID19. I’d like to thank the entire team at @Synairgenplc and @NIAIDNews for all their hard work and dedication, and everyone for their support so far.

[Synairgen @Synairgenplc]

We are pleased to share that #SNG001, our investigational inhaled interferon beta, is advancing to Phase 3 in the NIH-sponsored #ACTIV2 COVID-19 trial. You can read the full announcement here: https://t.co/oPer057K7R